https://orcid.org/0000-0001-6255-0006
References
- Jørgensen JT. Twenty-five years with companion diagnostics. Chin Clin Oncol. 2023;12(6):65. doi: 10.21037/cco-23-96
- FDA. In vitro companion diagnostic devices. Guidance for industry and food and drug administration staff. 2014 Aug [cited 2023 Oct 29]. Available from: https://www.fda.gov/media/81309/download?attachment
- European Union. Regulation (EU) 2017/746 of the European Parliament and of the council of 5 April 2017 on in vitro diagnostic medical devices and repealing directive 98/79/EC and commission decision 2010/227/EU. Official Journal of the European Union. 2017 Apr.
- FDA. Medical devices; laboratory developed tests. A proposed rule by the FDA on 10/03/2023. [cited 2023 Oct 29]. Available from: https://www.federalregister.gov/documents/2023/10/03/2023-21662/medical-devices-laboratory-developed-tests
- European Union. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. [cited 2023 Nov 3]. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:31998L0079&from=EN
- Jørgensen JT Companion and complementary diagnostics as tools of precision medicine. Elsevier Reference Collection In Biomedical Sciences. 2023. [cited 2023 Nov 6]. Available from: https://www.sciencedirect.com/science/article/abs/pii/B9780128240106000423
- Bogen SA. A root cause analysis into the high error rate in clinical immunohistochemistry. Appl Immunohistochem Mol Morphol. 2019;27(5):329–338. doi: 10.1097/PAI.0000000000000750
- Vyberg M, Nielsen S. Proficiency testing in immunohistochemistry—experiences from Nordic immunohistochemical quality control (NordiQC). Virchows Arch. 2016;468(1):19–29. doi: 10.1007/s00428-015-1829-1
- Vyberg M, Nielsen S, Røge R, et al. Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests. BMC Health Serv Res. 2015;15(1):352. doi: 10.1186/s12913-015-1018-6
- Fernandez AI, Liu M, Bellizzi A, et al. Examination of Low ERBB2 Protein Expression in breast cancer Tissue. JAMA Oncol. 2022;8(4):1–4. doi: 10.1001/jamaoncol.2021.7239
- Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in Previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. doi: 10.1056/NEJMoa2203690
- FDA. The public health evidence for FDA oversight of laboratory developed tests: 20 case studies 2015 Nov 16 [cited 2023 Nov 6]. Available from: https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM472777.pdf
- Pfeifer JD, Loberg R, Lofton-Day C, et al. Reference samples to compare next-generation sequencing test performance for oncology therapeutics and diagnostics. Am J Clin Pathol. 2022;157(4):628–638. doi: 10.1093/ajcp/aqab164
- Vega DM, Yee LM, McShane LM, et al. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the friends of cancer research TMB harmonization project. Ann Oncol. 2021;32(12):1626–1636. doi: 10.1016/j.annonc.2021.09.016
- Quy PN, Fukuyama K, Kanai M, et al. Inter-assay variability of next-generation sequencing-based gene panels. BMC Med Genomics. 2022;15(1):86. doi: 10.1186/s12920-022-01230-y
- FDA: Draft Guidance for Industry, Food and Drug Administration Staff, and clinical laboratories on the Framework for Regulatory Oversight of Laboratory developed tests (LDTs). 2014 Oct 3 [cited 2024 Jan 27]. Available from: https://www.fda.gov/media/89841/download
- Robinson SA, Carter AR, Brindley DA. The changing regulatory landscape for laboratory developed tests. The Regulatory Affairs Professionals Society. Regulatory Focus, 2021 Aug [cited 2024 Jan 28]. Available from: https://www.raps.org/News-and-Articles/News-Articles/2021/8/The-changing-regulatory-landscape-for-laboratory-d